感染症治療薬の市場規模、シェア、動向分析レポート：感染症別、薬剤クラス別、流通チャネル別、地域別、セグメント予測、2025年～2030年

感染症治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の感染症治療薬市場規模は2030年までに2,839億1,000万米ドルに達し、2025年から2030年までのCAGRは3.5％を記録すると予測されています。

同市場は主に、ヒト免疫不全ウイルス（HIV）、ヒトパピローマウイルス（HPV）、結核、肝炎の症例数が世界的に増加していることが要因となっています。

政府機関や民間企業は、感染症の予防、診断、治療のためにヘルスケア分野に多額の投資を行っており、感染症を治療するための新薬開拓への投資の増加や、これらの疾患に関する意識向上のためのイニシアチブの増加が、予測期間中の市場を押し上げると予想されます。さらに、特許切れの増加やジェネリック医薬品の市場参入は、価格の安さから感染症治療薬の需要を高めると予想されます。

さらに、これらの感染症の診断と治療に対する償還が利用可能であり、これらの疾患の発生率が高い地域でメーカーが医薬品を無料で配布していることも、市場の成長をさらに促進する要因として期待されています。しかし、抗感染症薬の普及率の低さ、偽造薬の多さが、予測期間中の市場成長抑制要因になると予想されます。

北米市場は2016年に最大のシェアを占めました。多数の製造業者の存在、有利な償還シナリオ、医療費の増加が、この地域が最大のシェアを占める主な要因です。しかし、アジア太平洋地域は2017年から2025年にかけて最も高い成長率を示す可能性が高いです。感染症の有病率の高さ、アジア諸国の経済状況の改善、感染症治療の普及に向けた政府のイニシアティブの高まり、資金調達活動の活発化などが、予測期間中にこの地域が最も高い成長率を示す要因です。

感染症治療薬市場のレポートハイライト

• 2024年のシェアはウイルス感染症が42.58%で市場を独占。寄生虫感染症分野は、有病率の増加、薬剤耐性の上昇、マラリア、リーシュマニア症、住血吸虫症をターゲットとした世界の保健イニシアティブに牽引され、最も急成長している市場です。
• ワクチンは2024年に32.75%のシェアを占め、抗感染症薬市場を独占しています。これは、疾患有病率の上昇、認知度の向上、政府の強力な予防接種プログラムに牽引されています。抗寄生虫薬分野は、マラリア、リーシュマニア症、その他の寄生虫感染症の有病率の上昇により大きな成長を遂げています。
• 病院薬局は、世界の入院件数の増加に牽引され、2024年の売上シェア52.19％で市場を独占しています。その他の薬局分野は、感染症治療薬へのアクセシビリティと利便性を高めるオンライン薬局の導入増加により、急速な成長を遂げています。
• 2024年の感染症治療薬市場では、北米が世界シェアの38.09%を占め、主導的な地位を占めています。アジア太平洋地域の感染症治療薬市場は、細菌・ウイルス感染症の流行の増加とヘルスケアインフラの改善により拡大しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 感染症治療薬市場の変数、動向、範囲

• 市場系統の見通し
• 市場力学
  • 市場成長要因分析
  • 市場抑制要因分析
• 感染症治療薬に対する耐性の出現とそれに伴う副作用
• ビジネス環境分析
  • 業界分析- ポーターのファイブフォース分析
  • PESTLE分析
  • パイプライン分析

第4章 感染症治療薬市場：感染症別ビジネス分析

• 感染症市場シェア、2024年および2030年
• 感染症セグメントダッシュボード
• 市場規模、予測、動向分析（感染症別、2018～2030年）
• 細菌感染症
• ウイルス感染
• 真菌感染症
• 寄生虫感染症

第5章 感染症治療薬市場：薬剤クラス別ビジネス分析

• 薬剤クラス市場シェア、2024年および2030年
• 薬剤クラスセグメントダッシュボード
• 市場規模と予測および動向分析（薬剤クラス別、2018～2030年）
• 抗菌剤
• 抗ウイルス薬
• 抗真菌薬
• 抗寄生虫薬
• ワクチン
• その他

第6章 感染症治療薬市場：流通チャネル別ビジネス分析

• 流通チャネル市場シェア、2024年および2030年
• 流通チャネルセグメントダッシュボード
• 市場規模、予測、動向分析（流通チャネル別、2018～2030年）
• 病院薬局
• 小売薬局
• その他

第7章 感染症治療薬市場：地域別推定・動向分析

• 地域別市場シェア分析、2024年および2030年
• 地域市場ダッシュボード
• 市場規模と予測動向分析、2018年から2030年まで：
• 北米
  • 国別、2018年～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東およびアフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 参入企業概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • Pfizer Inc.
  • AbbVie.
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb
  • Merck &Co., Inc.
  • Sandoz International GmbH
  • B. Braun SE
  • Xellia Pharmaceuticals
  • Mankind Pharma
  • Bayer AG
  • AstraZeneca
  • Boehringer Ingelheim International GmbH.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviation
• Table 3 List of Parameters
• Table 4 List of Distributors
• Table 5 Global Infectious Disease Therapeutics Market, By Region, 2018 - 2030 (USD Million)
• Table 6 Global Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 7 Global Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 8 Global Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 9 North America Infectious Disease Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 10 North America Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 11 North America Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 12 North America Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 13 U.S. Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 14 U.S. Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 15 U.S. Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 16 Canada Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 17 Canada Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 18 Canada Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 19 Mexico Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 20 Mexico Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 21 Mexico Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 22 Europe Infectious Disease Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 23 Europe Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 24 Europe Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 25 Europe Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 26 Germany Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 27 Germany Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 28 Germany Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 29 UK Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 30 UK Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 31 UK Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 32 France Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 33 France Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 34 France Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 35 Italy Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 36 Italy Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 37 Italy Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 38 Spain Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 39 Spain Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 40 Spain Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 41 Denmark Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 42 Denmark Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 43 Denmark Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 44 Sweden Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 45 Sweden Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 46 Sweden Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 47 Norway Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 48 Norway Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 49 Norway Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific Infectious Disease Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 51 Asia Pacific Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 52 Asia Pacific Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 53 Asia Pacific Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 54 Japan Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 55 Japan Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 56 Japan Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 57 China Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 58 China Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 59 China Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 60 India Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 61 India Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 62 India Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 63 South Korea Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 64 South Korea Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 65 South Korea Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 66 Australia Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 67 Australia Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 68 Australia Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 69 Thailand Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 70 Thailand Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 71 Thailand Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 72 Latin America Infectious Disease Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 73 Latin America Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 74 Latin America Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 75 Latin America Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 76 Brazil Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 77 Brazil Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 78 Brazil Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 79 Argentina Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 80 Argentina Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 81 Argentina Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 82 Middle East & Africa Infectious Disease Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 83 Middle East & Africa Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 84 Middle East & Africa Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 85 Middle East & Africa Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 86 Saudi Arabia Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 88 Saudi Arabia Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 89 South Africa Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 90 South Africa Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 91 South Africa Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 92 UAE Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 93 UAE Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 94 UAE Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
• Table 95 Kuwait Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
• Table 96 Kuwait Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 97 Kuwait Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Astaxanthin market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Value chain based sizing & forecasting
• Fig. 6 QFD modelling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Source and product segment snapshot
• Fig. 10 Application segment snapshot
• Fig. 11 Competitive landscape snapshot
• Fig. 12 Parent market value, 2024 (USD Billion)
• Fig. 13 Market trends & outlook
• Fig. 14 Porter's five forces analysis
• Fig. 15 PESTEL analysis
• Fig. 16 Infectious Disease Therapeutics Market Outlook Key Takeaways
• Fig. 17 Infectious Disease Therapeutics Market: Infection Movement Analysis
• Fig. 18 Global Infectious Disease Therapeutics Market, by Infection, 2018 - 2030 (USD Million)
• Fig. 19 Bacterial Infections Market, 2018 - 2030 (USD Million)
• Fig. 20 Viral Infections Market, 2018 - 2030 (USD Million)
• Fig. 21 Human Immunodeficiency Virus (HIV/AIDS) Market, 2018 - 2030 (USD Million)
• Fig. 22 Hepatitis (Hepatitis B, Hepatitis C) Market, 2018 - 2030 (USD Million)
• Fig. 23 Influenza Market, 2018 - 2030 (USD Million)
• Fig. 24 Other Viral Infections Market, 2018 - 2030 (USD Million)
• Fig. 25 Fungal Infections Market, 2018 - 2030 (USD Million)
• Fig. 26 Parasitic Infections Market, 2018 - 2030 (USD Million)
• Fig. 27 Global Infectious Disease Therapeutics Market: Drug Class Movement Analysis
• Fig. 28 Global Infectious Disease Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Fig. 29 Antibacterials Market, 2018 - 2030 (USD Million)
• Fig. 30 Antivirals Market, 2018 - 2030 (USD Million)
• Fig. 31 Antifungals Market, 2018 - 2030 (USD Million)
• Fig. 32 Antiparasitic Drugs Market, 2018 - 2030 (USD Million)
• Fig. 33 Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 34 Others Market, 2018 - 2030 (USD Million)
• Fig. 35 Global Infectious Disease Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Fig. 36 Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• Fig. 37 Retail Pharmacies Market, 2018 - 2030 (USD Million)
• Fig. 38 Others Market, 2018 - 2030 (USD Million)
• Fig. 39 Regional marketplace: Key takeaways
• Fig. 40 North America infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 U.S. infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Canada infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Mexico infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Europe infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 UK infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Germany infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 France infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Italy infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Spain infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Denmark infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Sweden infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Norway infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 Asia Pacific infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Japan infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 China infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 India infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Australia infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Thailand infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 South Korea infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Latin America infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Brazil infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 Argentina infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 MEA infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 South Africa infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Saudi Arabia infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 UAE infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Kuwait infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 List of key emerging company's/disruptors/innovators

Infectious Disease Therapeutics Market Growth & Trends:

The global infectious disease therapeutics market size is expected to reach USD 283.91 billion by 2030, registering a CAGR of 3.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by increasing number of Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), TB, and hepatitis cases globally.

Government and private organizations are investing heavily in the healthcare sector to prevent, diagnose, and treat infectious diseases; rising investments for development of new drugs to treat infectious diseases, and increasing number of initiatives for creating awareness about these conditions are expected to boost the market during the forecast period. Furthermore, increasing number of patent expirations and entry of generic drugs in the market are expected to increase the demand for infectious disease therapeutics due to their low prices.

In addition, availability of reimbursement for diagnosis & treatment of these infections and free distribution of drugs by manufacturers in regions with high incidence of these diseases are factors further expected to propel the market growth. However, low penetration rate of anti-infective and availability of large number of counterfeit drugs are expected to restraint the market growth during the forecast period.

North American market held the largest share in 2016. Presence of large number of manufacturers, favorable reimbursement scenario, and increasing healthcare expenditure are major factors responsible for the largest share held by this region. However, Asia Pacific is likely to grow at the highest rate between 2017 and 2025. High prevalence of infectious diseases; improving economic conditions in Asian countries, rising government initiatives to increase the adoption of treatments for infectious diseases, and rising funding activities are factors that can be attributed for the highest growth rate of this region during the forecast period.

Infectious Disease Therapeutics Market Report Highlights:

• Viral infections dominated the market with a 42.58% share in 2024. The parasitic infections segment is the fastest-growing market, driven by increasing prevalence, rising drug resistance, and global health initiatives targeting malaria, leishmaniasis, and schistosomiasis.
• Vaccines dominated the anti-infective agents market with a 32.75% share in 2024, driven by rising disease prevalence, growing awareness, and strong government immunization programs. The antiparasitic drugs segment is experiencing significant growth due to the rising prevalence of malaria, leishmaniasis, and other parasitic infections.
• Hospital pharmacies dominated the market with a revenue share of 52.19% in 2024, driven by the rising number of hospitalizations globally.The other pharmacy segment is experiencing rapid growth due to the increasing adoption of online pharmacies, which enhance accessibility and convenience for infectious disease therapeutics.
• North America holds a leading position in the 2024 infectious disease therapeutics market, accounting for 38.09% of the global share. The infectious disease therapeutics market in Asia Pacific is expanding due to the rising prevalence of bacterial and viral infections and improving healthcare infrastructure.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Infection
  • 1.2.2. Drug Class
  • 1.2.3. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Infectious Disease Therapeutics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing incidence of infectious diseases
    • 3.2.1.2. Increasing incidence of infectious diseases
    • 3.2.1.3. Rising initiatives for the awareness of infectious diseases
  • 3.2.2. Market Restraint Analysis
• 3.3. 3.3.1 Emergence of resistance to infectious disease therapeutic drugs and adverse effects associated with them
• 3.4. Business Environment Analysis
  • 3.4.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.4.1.1. Supplier Power
    • 3.4.1.2. Buyer Power
    • 3.4.1.3. Substitution Threat
    • 3.4.1.4. Threat of New Entrants
    • 3.4.1.5. Competitive Rivalry
  • 3.4.2. PESTLE Analysis
  • 3.4.3. Pipeline Analysis

Chapter 4. Infectious Disease Therapeutics Market: Infections Business Analysis

• 4.1. Infections Market Share, 2024 & 2030
• 4.2. Infections Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Infections, 2018 to 2030 (USD Million)
• 4.4. Bacterial Infections
  • 4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 4.5. Viral Infections
  • 4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.2. Human Immunodeficiency Virus (HIV/AIDS)
    • 4.5.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.3. Hepatitis (Hepatitis B, Hepatitis C)
    • 4.5.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.4. Influenza
    • 4.5.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.5. Others
    • 4.5.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 4.6. Fungal Infections
  • 4.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 4.7. Parasitic Infections
  • 4.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Infectious Disease Therapeutics Market: Drug Class Business Analysis

• 5.1. Drug Class Market Share, 2024 & 2030
• 5.2. Drug Class Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
• 5.4. Antibacterials
  • 5.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 5.5. Antivirals
  • 5.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 5.6. Antifungals
  • 5.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 5.7. Antiparasitic Drugs
  • 5.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 5.8. Vaccines
  • 5.8.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Infectious Disease Therapeutics Market: Distribution Channel Business Analysis

• 6.1. Distribution Channel Market Share, 2024 & 2030
• 6.2. Distribution Channel Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 6.4. Hospitals Pharmacies
  • 6.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 6.5. Retail Pharmacies
  • 6.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Infectious Disease Therapeutics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America Infectious Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Framework
    • 7.4.2.5. U.S. Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Framework
    • 7.4.3.5. U.S. Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Framework
    • 7.4.4.5. Mexico Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Framework
    • 7.5.2.5. UK Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Framework
    • 7.5.3.5. Germany Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement Framework
    • 7.5.4.5. France Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Target Disease Prevalence
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Reimbursement Framework
    • 7.5.5.5. Italy Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Target Disease Prevalence
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Reimbursement Framework
    • 7.5.6.5. Spain Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Target Disease Prevalence
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement Framework
    • 7.5.7.5. Denmark Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Target Disease Prevalence
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement Framework
    • 7.5.8.5. Sweden Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Target Disease Prevalence
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement Framework
    • 7.5.9.5. Norway Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Framework
    • 7.6.2.5. Japan Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Framework
    • 7.6.3.5. China Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Framework
    • 7.6.4.5. India Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Framework
    • 7.6.5.5. Australia Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Target Disease Prevalence
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement Framework
    • 7.6.6.5. South Korea Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Target Disease Prevalence
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement Framework
    • 7.6.7.5. Thailand Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Target Disease Prevalence
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement Framework
    • 7.7.2.5. Brazil Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Target Disease Prevalence
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement Framework
    • 7.7.3.5. Argentina Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Middle East and Africa
  • 7.8.1. Middle East and Africa Infectious Disease Therapeutics Market Estimates and Forecasts, 2017 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Target Disease Prevalence
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement Framework
    • 7.8.2.5. South Africa Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Target Disease Prevalence
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement Framework
    • 7.8.3.5. Saudi Arabia Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Target Disease Prevalence
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement Framework
    • 7.8.4.5. UAE Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Target Disease Prevalence
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement Framework
    • 7.8.5.5. Kuwait Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Pfizer Inc.
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Infection Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. AbbVie.
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Infection Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Gilead Sciences, Inc.
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Infection Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Bristol-Myers Squibb
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Infection Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Merck & Co., Inc.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Infection Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Sandoz International GmbH
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Infection Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. B. Braun SE
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Infection Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Xellia Pharmaceuticals
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Infection Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Mankind Pharma
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Infection Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Bayer AG
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Infection Benchmarking
    • 8.5.10.4. Strategic Initiatives
  • 8.5.11. AstraZeneca
    • 8.5.11.1. Overview
    • 8.5.11.2. Financial Performance
    • 8.5.11.3. Infection Benchmarking
    • 8.5.11.4. Strategic Initiatives
  • 8.5.12. Boehringer Ingelheim International GmbH.
    • 8.5.12.1. Overview
    • 8.5.12.2. Financial Performance
    • 8.5.12.3. Infection Benchmarking
    • 8.5.12.4. Strategic Initiatives
  • 8.5.13. Novartis AG
    • 8.5.13.1. Overview
    • 8.5.13.2. Financial Performance
    • 8.5.13.3. Infection Benchmarking
    • 8.5.13.4. Strategic Initiatives
  • 8.5.14. F. Hoffmann-La Roche Ltd
    • 8.5.14.1. Overview
    • 8.5.14.2. Financial Performance
    • 8.5.14.3. Infection Benchmarking
    • 8.5.14.4. Strategic Initiatives